Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-09-29Actual
Enrollment · participants683Actual
Source updated2024-10-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.